Hydroxyzine Pamoate recalls
The FDA has published 3 recalls involving Hydroxyzine Pamoate since 2014. The latest was reported on 15 Jun 2022. Most were for manufacturing (cgmp) deviations. Teva Pharmaceuticals U has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls3since 2014
Last 12 months0reported
Class I00% of total
Ongoing0latest 15 Jun 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 3 100%Class III 0 0%
Why hydroxyzine pamoate is recalled
Companies
By year
All hydroxyzine pamoate recalls, newest first
3 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | HydrOXYzine Pamoate Capsules, USP, 50 mg recalledHydroxyzine Pamoate | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Teva Hydroxyzine Pamoate Capsules, USP, 25 mg recalledHydroxyzine Pamoate | Teva Pharmaceuticals U | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Teva Hydroxyzine Pamoate Capsules, USP, 100 mg recalledHydroxyzine Pamoate | Teva Pharmaceuticals U | Manufacturing (CGMP) Deviations | Nationwide |
Should you stop taking Hydroxyzine Pamoate?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.